HSV1716

AXP000073.1 · Oncolytic virus

Platform
HSV-1 (strain 17+, RL1/ICP34.5 deleted)
Originator
University of Glasgow (MRC Institute of Virology)
Sponsor
Virttu Biologics (Sorrento Therapeutics)

Names

NameTypeSource
HSV1716preferred name, codecurator, ncit
Seprehvirbrandncit
RL1 mutant HSV-1 1716synonymcurator

Virus

Role
Oncolytic
Family
Orthoherpesviridae
Virus
herpes simplex virus 1 (NCBI Taxonomy 10298)
Strain
17+
Replication
conditionally replicating
Modifications
both copies of RL1 (ICP34.5) deleted; no transgene
Route
intratumoral, intracerebral, intravenous, intrapleural
Source
evidence

Cross-references

NCI Thesaurus
C84840
FDA UNII
26WEP2905N

Approvals

No regulatory approval recorded.

Clinical trials (3)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT02031965Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade Glioma That Can Be Removed By SurgeryTerminatedPhase 12013-122016-052Recurrent Childhood Anaplastic Astrocytoma; Recurrent Childhood Anaplastic Oligoastrocytoma; Recurrent Childhood Anaplastic Oligodendroglioma; Recurrent Childhood Giant Cell Glioblastoma; Recurrent Childhood Glioblastoma; Recurrent Childhood Gliomatosis Cerebri; Recurrent Childhood Gliosarcoma
NCT01721018Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma.CompletedPhase 1/22012-102016-11-1412Malignant Pleural Mesothelioma
NCT00931931HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid TumorsCompletedPhase 12010-032018-03-1918Clival Chordoma; Ewing Sarcoma; Malignant Peripheral Nerve Sheath Tumor; Neuroblastoma; Non-CNS Solid Tumors; Osteosarcoma; Rhabdomyosarcoma; Soft Tissue Sarcoma; Wilms Tumor

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 33160198Oncolytic herpesvirus therapy for mesothelioma - A phase I/IIa trial of intrapleural administration of HSV1716.Lung cancer (Amsterdam, Netherlands)2020name in title: HSV1716
PMID 31570234First-in-Human Intravenous Seprehvir in Young Cancer Patients: A Phase 1 Clinical Trial.Molecular therapy : the journal of the American Society of Gene Therapy2019name in title: Seprehvir
PMID 28495911Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients.Clinical cancer research : an official journal of the American Association for Cancer Research2017name in title: HSV1716
PMID 18615711Potential for efficacy of the oncolytic Herpes simplex virus 1716 in patients with oral squamous cell carcinoma.Head & neck2008name in abstract: HSV1716
PMID 16829761Assessment of 123I-FIAU imaging of herpes simplex viral gene expression in the treatment of glioma.Nuclear medicine communications2006name in abstract: HSV1716
PMID 11229673Intralesional injection of herpes simplex virus 1716 in metastatic melanoma.Lancet (London, England)2001name in abstract: HSV1716

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 41705010A Decade of Oncolytic Virotherapy in Pediatric Cancers: A Systematic Review of Safety, Immune Awakening, and Emerging Efficacy.Cureus2026name in abstract: HSV1716
PMID 41741902Clinical and translational progress in oncolytic virotherapy for pediatric CNS tumors.Journal of neuro-oncology2026name in abstract: HSV1716
PMID 42072616Exercise Boosts the Immune System and Enhances Immunotherapy Responses in Pancreatic Cancer and Mesothelioma.Biomolecules2026name in abstract: HSV1716
PMID 42609452Oncolytic HSV1716 attenuates tumor-killing activity of infected primary NK cells.Frontiers in immunology2026name in title: HSV1716
PMID 40685482Oncolytic virotherapy and tumor microenvironment modulation.Clinical and experimental medicine2025name in abstract: HSV1716
PMID 39239066Synergistic effects of herpes oncolytic virus and cyclophosphamide for recurrent malignant glioma: a narrative review.Annals of medicine and surgery (2012)2024name in abstract: HSV1716
PMID 36992311HSV1716 Prevents Myeloma Cell Regrowth When Combined with Bortezomib In Vitro and Significantly Reduces Systemic Tumor Growth in Mouse Models.Viruses2023name in title: HSV1716
PMID 37749907Oncolytic virotherapies for pediatric tumors.Expert opinion on biological therapy2023name in abstract: HSV1716
PMID 35076148Nanobugs as Drugs: Bacterial Derived Nanomagnets Enhance Tumor Targeting and Oncolytic Activity of HSV-1 Virus.Small (Weinheim an der Bergstrasse, Germany)2022name in abstract: HSV1716
PMID 35782876Inconsistencies in Modeling the Efficacy of the Oncolytic Virus HSV1716 Reveal Potential Predictive Biomarkers for Tolerability.Frontiers in molecular biosciences2022name in title: HSV1716
PMID 33298589Macrophages Mediate the Antitumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors.Molecular cancer therapeutics2021name in title: HSV1716
PMID 29543735High Mobility Group Box 1 Influences HSV1716 Spread and Acts as an Adjuvant to Chemotherapy.Viruses2018name in title: HSV1716
PMID 29896663Oncolytic Virotherapy by HSV.Advances in experimental medicine and biology2018name in abstract: HSV1716
PMID 28147331Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation.Oncotarget2017name in abstract: HSV1716
PMID 28547002Oncolytic Herpes Simplex Virus Inhibits Pediatric Brain Tumor Migration and Invasion.Molecular therapy oncolytics2017name in abstract: HSV1716
PMID 29034312TGF-β Inhibition Improves Oncolytic Herpes Viroimmunotherapy in Murine Models of Rhabdomyosarcoma.Molecular therapy oncolytics2017name in abstract: HSV1716
PMID 26583803Neuroblastomas vary widely in their sensitivities to herpes simplex virotherapy unrelated to virus receptors and susceptibility.Gene therapy2016name in abstract: Seprehvir
PMID 26284300Directing cell therapy to anatomic target sites in vivo with magnetic resonance targeting.Nature communications2015name in abstract: Seprehvir
PMID 27508184Potent efficacy signals from systemically administered oncolytic herpes simplex virus (HSV1716) in hepatocellular carcinoma xenograft models.Journal of hepatocellular carcinoma2014name in title: HSV1716
PMID 22414636In vivo evaluation of a cancer therapy strategy combining HSV1716-mediated oncolysis with gene transfer and targeted radiotherapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine2012name in title: HSV1716
PMID 22595793Expression of inhibitor of growth 4 by HSV1716 improves oncolytic potency and enhances efficacy.Cancer gene therapy2012name in title: HSV1716
PMID 20205051HSV-1-derived helper-independent defective vectors, replicating vectors and amplicon vectors, for the treatment of brain diseases.Current opinion in drug discovery & development2010name in abstract: HSV1716
PMID 19528476Antitumor activity of a selectively replication competent herpes simplex virus (HSV) with enzyme prodrug therapy.Anticancer research2009name in abstract: HSV1716
PMID 17928799GADD34 gene restores virulence in viral vector used in experimental stroke study.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism2008name in abstract: HSV1716
PMID 18458533Herpes virus oncolytic therapy reverses tumor immune dysfunction and facilitates tumor antigen presentation.Cancer biology & therapy2008name in abstract: HSV1716
PMID 18701918A strategy for systemic delivery of the oncolytic herpes virus HSV1716: redirected tropism by antibody-binding sites incorporated on the virion surface as a glycoprotein D fusion protein.Gene therapy2008name in title: HSV1716
PMID 17763002Cytotoxic effects of the oncolytic herpes simplex virus HSV1716 alone and in combination with cisplatin in head and neck squamous cell carcinoma.Acta oto-laryngologica2007name in title: HSV1716
PMID 16574492Oncolytic viruses derived from the gamma34.5-deleted herpes simplex virus recombinant R3616 encode a truncated UL3 protein.Molecular therapy : the journal of the American Society of Gene Therapy2006name in abstract: HSV1716
PMID 15925544HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer.Molecular therapy : the journal of the American Society of Gene Therapy2005name in abstract: HSV1716
PMID 15960607Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma.Human gene therapy2005name in abstract: HSV1716
PMID 16014957Herpes simplex virus type 1 strain HSV1716 grown in baby hamster kidney cells has altered tropism for nonpermissive Chinese hamster ovary cells compared to HSV1716 grown in vero cells.Journal of virology2005name in title: HSV1716
PMID 16787326Assessment in vitro of a novel therapeutic strategy for glioma, combining herpes simplex virus HSV1716-mediated oncolysis with gene transfer and targeted radiotherapy.Medicinal chemistry (Shariqah (United Arab Emirates))2005name in title: HSV1716
PMID 15334111HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival.Gene therapy2004name in title: HSV1716
PMID 12898637Proliferative activity and in vitro replication of HSV1716 in human metastatic brain tumours.The journal of gene medicine2003name in title: HSV1716
PMID 14682372Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas.Journal of neuro-oncology2003name in abstract: HSV1716
PMID 11960316The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study.Gene therapy2002name in title: HSV1716
PMID 12170384HSV1716 persistence in primary human glioma cells in vitro.Gene therapy2002name in title: HSV1716
PMID 11020355Effect of preexisting anti-herpes immunity on the efficacy of herpes simplex viral therapy in a murine intraperitoneal tumor model.Molecular therapy : the journal of the American Society of Gene Therapy2000name in abstract: HSV1716
PMID 10389942Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer.Clinical cancer research : an official journal of the American Association for Cancer Research1999name in abstract: HSV1716
PMID 10585055Oncolytic therapy using a mutant type-1 herpes simplex virus and the role of the immune system.The Annals of thoracic surgery1999name in abstract: HSV1716
PMID 10609661Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer.Human gene therapy1999name in title: HSV1716
PMID 9012475Use of a "replication-restricted" herpes virus to treat experimental human malignant mesothelioma.Cancer research1997name in abstract: HSV1716
PMID 9182825Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant.The Journal of investigative dermatology1997name in abstract: HSV1716
PMID 9400985Herpes simplex virus 1716, an ICP 34.5 null mutant, is unable to replicate in CV-1 cells due to a translational block that can be overcome by coinfection with SV40.The Journal of general virology1997name in abstract: HSV1716
PMID 8806577Herpes simplex 1716--an ICP 34.5 mutant--is severely replication restricted in human skin xenografts in vivo.Virology1996name in abstract: HSV1716

NIH grants

ProjectTitleOrganisationPIYearsLinked by
R33NS128191Development of murine glioblastoma model for oncolytic HSV therapyLSU HEALTH SCIENCES CENTERKAUR, BALVEEN2026–2026name in abstract: HSV1716
R61NS128191Development of murine glioblastoma model for oncolytic HSV therapyAUGUSTA UNIVERSITYKAUR, BALVEEN2024–2025name in abstract: HSV1716
R21CA191544CendR peptide-mediated enhancement of systemic oncolytic herpes virotherapyRESEARCH INST NATIONWIDE CHILDREN'S HOSPCRIPE, TIMOTHY P2015–2016name in abstract: HSV1716
R01FD003717Phase I Study of HSV1716 in Pediatric Non-CNS Solid Tumors,IND 13196 12/04/2006RESEARCH INST NATIONWIDE CHILDREN'S HOSPCRIPE, TIMOTHY P2010–2014name in title: HSV1716

Notes

First engineered oncolytic HSV given to humans (glioma, Edinburgh/Glasgow, published 2000). Later sponsors Crusade Laboratories then Virttu Biologics; Virttu acquired by Sorrento Therapeutics 2017. No recent trials found; treated as discontinued.

How to cite

HSV1716 (AXP000073.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000073.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.